CA2598613A1 - Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors - Google Patents
Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors Download PDFInfo
- Publication number
- CA2598613A1 CA2598613A1 CA002598613A CA2598613A CA2598613A1 CA 2598613 A1 CA2598613 A1 CA 2598613A1 CA 002598613 A CA002598613 A CA 002598613A CA 2598613 A CA2598613 A CA 2598613A CA 2598613 A1 CA2598613 A1 CA 2598613A1
- Authority
- CA
- Canada
- Prior art keywords
- use according
- defibrotide
- angiogenesis
- oligodeoxyribonucleotides
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 24
- JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 21
- 229960004120 defibrotide Drugs 0.000 title claims abstract description 21
- 230000001419 dependent effect Effects 0.000 title claims abstract description 8
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 title claims abstract description 8
- 238000000605 extraction Methods 0.000 claims abstract description 5
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 4
- 241001465754 Metazoa Species 0.000 claims abstract description 4
- 230000009471 action Effects 0.000 claims abstract description 4
- 235000013311 vegetables Nutrition 0.000 claims abstract description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 3
- 201000008275 breast carcinoma Diseases 0.000 claims abstract description 3
- 210000000056 organ Anatomy 0.000 claims abstract description 3
- 230000000259 anti-tumor effect Effects 0.000 claims abstract 4
- 239000004480 active ingredient Substances 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 6
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 3
- 229960002930 sirolimus Drugs 0.000 claims description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- QPNKYNYIKKVVQB-UHFFFAOYSA-N crotaleschenine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2=CCN3C2C1CC3 QPNKYNYIKKVVQB-UHFFFAOYSA-N 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- QVCMHGGNRFRMAD-XFGHUUIASA-N monocrotaline Chemical compound C1OC(=O)[C@](C)(O)[C@@](O)(C)[C@@H](C)C(=O)O[C@@H]2CCN3[C@@H]2C1=CC3 QVCMHGGNRFRMAD-XFGHUUIASA-N 0.000 claims 1
- QVCMHGGNRFRMAD-UHFFFAOYSA-N monocrotaline Natural products C1OC(=O)C(C)(O)C(O)(C)C(C)C(=O)OC2CCN3C2C1=CC3 QVCMHGGNRFRMAD-UHFFFAOYSA-N 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 description 11
- 238000003556 assay Methods 0.000 description 8
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000005166 vasculature Anatomy 0.000 description 4
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 3
- 210000002358 circulating endothelial cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- -1 alkali-metal salt Chemical class 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000009764 endothelial cell sprouting Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2005A000336 | 2005-03-03 | ||
| IT000336A ITMI20050336A1 (it) | 2005-03-03 | 2005-03-03 | Formulazione ad attivita' anti-tumorale |
| US73140405P | 2005-10-28 | 2005-10-28 | |
| US60/731,404 | 2005-10-28 | ||
| PCT/EP2006/060304 WO2006094916A1 (en) | 2005-03-03 | 2006-02-27 | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2598613A1 true CA2598613A1 (en) | 2006-09-14 |
Family
ID=36572331
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002598613A Abandoned CA2598613A1 (en) | 2005-03-03 | 2006-02-27 | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
| CA2598072A Expired - Fee Related CA2598072C (en) | 2005-03-03 | 2006-02-27 | Formulations with anti-tumour action |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2598072A Expired - Fee Related CA2598072C (en) | 2005-03-03 | 2006-02-27 | Formulations with anti-tumour action |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20080194506A1 (enExample) |
| EP (2) | EP1853277A1 (enExample) |
| JP (2) | JP2008531647A (enExample) |
| KR (3) | KR20070121001A (enExample) |
| AU (2) | AU2006222044A1 (enExample) |
| CA (2) | CA2598613A1 (enExample) |
| IL (3) | IL185182A0 (enExample) |
| MX (2) | MX2007010754A (enExample) |
| WO (2) | WO2006094917A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20031714A1 (it) | 2003-09-05 | 2005-03-06 | Gentium Spa | Formazioni ad azione antitumorale. |
| EP1982722A1 (en) * | 2007-04-16 | 2008-10-22 | Gentium S.p.A. | Use of oligotide for the treatment of renal diseases |
| EP2103689A1 (en) * | 2008-03-19 | 2009-09-23 | Gentium S.p.A. | Synthetic phosphodiester oligonucleotides and therapeutical uses thereof |
| US8187897B2 (en) | 2008-08-19 | 2012-05-29 | International Business Machines Corporation | Fabricating product chips and die with a feature pattern that contains information relating to the product chip |
| DK2637672T3 (en) | 2010-11-12 | 2018-10-22 | Gentium S R L | DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD) |
| CN110079580B (zh) | 2012-06-22 | 2022-12-06 | 真蒂奥姆责任有限公司 | 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法 |
| EP3026122A1 (en) | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Cellular-based method for determining the potency of defibrotide |
| SG11202000952PA (en) | 2017-08-03 | 2020-02-27 | Jazz Pharmaceuticals Ireland Ltd | Formulations comprising a nucleic acid in a high concentration |
| MX2020010689A (es) | 2018-04-12 | 2021-01-20 | Jazz Pharmaceuticals Inc | Defibrotida para la prevencion y tratamiento del sindrome de liberacion de citocinas y la neurotoxicidad asociada con la inmunodeplecion. |
| US20220023533A1 (en) | 2018-12-07 | 2022-01-27 | Jazz Phrmaceticals Ireland Limited | Subcutaneous delivery of high concentration formulations |
| US20230190783A1 (en) | 2020-02-28 | 2023-06-22 | Jazz Pharmaceuticals Ireland Limited | Delivery of low viscosity formulations |
| TW202308659A (zh) | 2021-05-06 | 2023-03-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2154279A1 (de) * | 1970-11-03 | 1972-05-25 | Crinos Industria Farmaco | Medikamente für das fibrinolytische System |
| IT1043823B (it) * | 1970-11-03 | 1980-02-29 | Prephar | Procedimento per l estrazione di acidi nucleici da organi animali |
| US3899481A (en) * | 1970-11-03 | 1975-08-12 | Crinos Industria Farmaco | Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs |
| IT1170214B (it) * | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per la cura delle arteriopatie periferiche |
| IT1206341B (it) * | 1984-02-16 | 1989-04-14 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio. |
| US4694134A (en) * | 1985-05-28 | 1987-09-15 | Ajax Magnethermic Corporation | Apparatus for overheating edges of skelp for the production of compression welded pipe |
| US5223609A (en) * | 1986-04-17 | 1993-06-29 | Crinos Industria Farmacobiologica S.P.A. | Process for obtaining chemically defined and reproducible polydeoxyribonucleotides |
| IT1190313B (it) * | 1986-04-17 | 1988-02-16 | Crinos Industria Farmaco | Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante |
| US6699985B2 (en) * | 1991-08-21 | 2004-03-02 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
| US5977083A (en) * | 1991-08-21 | 1999-11-02 | Burcoglu; Arsinur | Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states |
| IT1252174B (it) * | 1991-12-09 | 1995-06-05 | Crinos Industria Farmaco | Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento |
| US5578716A (en) * | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
| AU754242B2 (en) * | 1997-04-28 | 2002-11-07 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
| JP2002512508A (ja) * | 1997-05-30 | 2002-04-23 | マクギル・ユニヴァーシティ | Ｄｎａメチルトランスフェラーゼゲノミック配列およびアンチセンスオリゴヌクレオチド |
| DE19740384A1 (de) * | 1997-09-08 | 1999-03-11 | Max Delbrueck Centrum | Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN |
| US7514414B2 (en) * | 2001-09-24 | 2009-04-07 | The United States Of America As Represented By The Department Of Health And Human Services | Suppressors of CpG oligonucleotides and methods of use |
| ITMI20031714A1 (it) * | 2003-09-05 | 2005-03-06 | Gentium Spa | Formazioni ad azione antitumorale. |
-
2006
- 2006-02-27 JP JP2007557486A patent/JP2008531647A/ja active Pending
- 2006-02-27 CA CA002598613A patent/CA2598613A1/en not_active Abandoned
- 2006-02-27 JP JP2007557485A patent/JP5714203B2/ja not_active Expired - Fee Related
- 2006-02-27 US US11/817,572 patent/US20080194506A1/en not_active Abandoned
- 2006-02-27 WO PCT/EP2006/060306 patent/WO2006094917A2/en not_active Ceased
- 2006-02-27 KR KR1020077023861A patent/KR20070121001A/ko not_active Withdrawn
- 2006-02-27 EP EP06708536A patent/EP1853277A1/en not_active Ceased
- 2006-02-27 AU AU2006222044A patent/AU2006222044A1/en not_active Abandoned
- 2006-02-27 KR KR1020077021114A patent/KR20070120954A/ko not_active Withdrawn
- 2006-02-27 US US11/817,575 patent/US20080194507A1/en not_active Abandoned
- 2006-02-27 AU AU2006222045A patent/AU2006222045B2/en not_active Ceased
- 2006-02-27 MX MX2007010754A patent/MX2007010754A/es not_active Application Discontinuation
- 2006-02-27 EP EP06708537A patent/EP1855697A2/en not_active Withdrawn
- 2006-02-27 WO PCT/EP2006/060304 patent/WO2006094916A1/en not_active Ceased
- 2006-02-27 KR KR1020077021110A patent/KR20070120953A/ko not_active Withdrawn
- 2006-02-27 MX MX2007010407A patent/MX2007010407A/es not_active Application Discontinuation
- 2006-02-27 CA CA2598072A patent/CA2598072C/en not_active Expired - Fee Related
-
2007
- 2007-08-09 IL IL185182A patent/IL185182A0/en active IP Right Grant
- 2007-08-09 IL IL185181A patent/IL185181A0/en unknown
- 2007-08-14 IL IL185258A patent/IL185258A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2598072A1 (en) | 2006-09-14 |
| US20080194506A1 (en) | 2008-08-14 |
| AU2006222044A1 (en) | 2006-09-14 |
| EP1855697A2 (en) | 2007-11-21 |
| AU2006222045A1 (en) | 2006-09-14 |
| IL185182A0 (en) | 2008-01-20 |
| JP2008531647A (ja) | 2008-08-14 |
| JP2008531646A (ja) | 2008-08-14 |
| IL185258A0 (en) | 2008-02-09 |
| WO2006094917A3 (en) | 2006-12-14 |
| EP1853277A1 (en) | 2007-11-14 |
| KR20070120953A (ko) | 2007-12-26 |
| US20080194507A1 (en) | 2008-08-14 |
| JP5714203B2 (ja) | 2015-05-07 |
| WO2006094916A1 (en) | 2006-09-14 |
| IL185258A (en) | 2010-12-30 |
| WO2006094917A2 (en) | 2006-09-14 |
| WO2006094917A8 (en) | 2008-01-31 |
| IL185181A0 (en) | 2008-01-20 |
| KR20070121001A (ko) | 2007-12-26 |
| MX2007010754A (es) | 2007-11-07 |
| MX2007010407A (es) | 2007-10-17 |
| KR20070120954A (ko) | 2007-12-26 |
| AU2006222045B2 (en) | 2011-10-20 |
| CA2598072C (en) | 2016-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes | |
| CA2598072C (en) | Formulations with anti-tumour action | |
| ES2523463T3 (es) | Composiciones para inhibir la angiogénesis | |
| Wu et al. | Exosomal B7-H3 facilitates colorectal cancer angiogenesis and metastasis through AKT1/mTOR/VEGFA pathway | |
| WO2011128115A1 (en) | Analogues of etoposide for the treatment of tumours | |
| Hoda et al. | Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy | |
| Wang et al. | Dually regulating the proliferation and the immune microenvironment of melanoma via nanoparticle-delivered siRNA targeting onco-immunologic CD155 | |
| Paz-García et al. | Beneficial effect of TLR4 blockade by a specific aptamer antagonist after acute myocardial infarction | |
| Liu et al. | G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice | |
| Hasenstein et al. | Efficacy of Tie2 receptor antagonism in angiosarcoma | |
| EP1867335B1 (en) | Oligodeoxyribonucleotides combined with rapamycin for treating cancer | |
| AU2007231651B2 (en) | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors | |
| KR20050007455A (ko) | 올리고뉴클레오티드를 이용하여 세포 성장을 억제하는 방법 | |
| JP2017178943A (ja) | 血管新生阻害薬 | |
| Zhang et al. | 5-Fluorouracil induces apoptosis of colorectal cancer cells | |
| Chen et al. | Comparison of tumor-derived total RNA and cell lysate on antitumor immune activity | |
| Thomas | An In Vivo Biocompatibility Analysis of A Novel Tissue Regeneration Matrix Using A Pig Model | |
| TW201233385A (en) | Use of tea polyphenols for treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer | |
| Zhang et al. | Biomimetic immortalized mesenchymal stem cell-based nanoparticles suppress orthotopic postsurgical glioma via CD73 targeting and chemotherapy | |
| Deutsch et al. | Radiotherapy for localized rectal cancer | |
| Huang et al. | Flavonoids from Millettia Speciosa Champ Inhibit the Migration and Angiogenesis of Prostate Cancer Cells | |
| Türkeri et al. | Intravesical chemotherapy | |
| Srivatsa et al. | 257 Role of Epidermal Growth Factor Receptor (EGFR) in Inflammation Induced Colorectal Cancers | |
| Wu et al. | 260 Enemy or Friend?–Cancer Cell Death by Epidermal Growth Factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20150227 |